Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence

21.06.2022 - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the results from the Phase 3 PROpel trial have been published in NEJM Evidence. Results from the trial showed that LYNPARZA in combination ...

Related Keywords

China ,Japan ,United States ,Canada ,American ,Noel Clarke ,Eliav Barr ,Cristian Massacesi ,Instagram ,Merck Research Laboratories ,American Society Of Clinical Oncology ,Linkedin ,Twitter ,University Of Manchester ,Data Monitoring Committee ,Statement Of Merck Co Inc ,Merck Co Inc ,Exchange Commission ,Astrazeneca ,Youtube ,European Union ,Facebook ,Salford Royal Hospitals ,Clinical Oncology ,Genitourinary Cancers Symposium ,Acute Myeloid Leukemia ,Fetal Toxicity ,Thromboembolic Events ,First Line Maintenance ,Advanced Ovarian ,First Line Maintenance Advanced Ovarian Cancer ,Maintenance Recurrent Ovarian ,Ovarian Cancer After ,More Lines ,Adjuvant Treatment ,High Risk Early Breast ,Negative Metastatic Breast ,Metastatic Pancreatic ,Metastatic Castration Resistant Prostate ,Positive Advanced Ovarian Cancer ,Line Maintenance ,Prescribing Information ,Looking Statement ,Litigation Reform Act ,Annual Report ,Merck Amp Co ,